Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel-Group, Phase 2b Study of LY3009104 in Patients With Active Rheumatoid Arthritis on Background Methotrexate Therapy

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel-Group, Phase 2b Study of LY3009104 in Patients With Active Rheumatoid Arthritis on Background Methotrexate Therapy

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Jun 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Baricitinib (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms JADA
  • Sponsors Eli Lilly and Company
  • Most Recent Events

    • 06 Jun 2020 Retrospective analysis of data from this study assessing quality and timing of the post-contrast MRI sequence can impact MRI-based exploratory endpoints in RA clinical trials when using novel computer-aided analysis tools presented at the 21st Annual Congress of the European League Against Rheumatism
    • 06 Mar 2019 Results of post-hoc pooled analysis of 5 trials (NCT01185353, NCT01469013, NCT00902486, NCT01710358 and NCT01721057) and an ongoing open-label, long-term extension (LTE) study ( NCT01885078), studying effect of select comorbidities on the efficacy and safety of baricitinib 4 mg once daily in patients with moderate-to-severe active RA published in the Annals of the Rheumatic Diseases.
    • 15 Sep 2018 Results published in The Journal of Rheumatology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top